We are committed to fighting prostate cancer. ORCA aims to significantly improve the lives of prostate cancer patients by developing safe and highly potent oncolytic virus immunotherapies.

Learn more

ORCA’s lead compound ORCA-010 is currently being prepared for clinical testing in patients with locally recurrent prostate cancer.

Learn more

CASES AGED 50 OR OLDER

MEN DIAGNOSED

IMPOTENT AFTER SURGERY

MEN WILL DIE